



**Haegarda® (C1 esterase inhibitor, human)  
Medication Precertification Request**

**Aetna Precertification Notification**  
Phone: 1-866-752-7021  
FAX: 1-888-267-3277

Page 1 of 2

(All fields must be completed and legible for precertification review.)

**For Medicare Advantage Part B:  
Please Use Medicare Request Form**

**Please indicate:**  Start of treatment: Start date \_\_\_\_ / \_\_\_\_ / \_\_\_\_  
 Continuation of therapy: Date of last treatment \_\_\_\_ / \_\_\_\_ / \_\_\_\_

**Precertification Requested By:** \_\_\_\_\_ **Phone:** \_\_\_\_\_ **Fax:** \_\_\_\_\_

**A. PATIENT INFORMATION**

First Name:		Last Name:	
Address:		City:	State: ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	Email:	
Current Weight: _____ lbs or _____ kgs		Height: _____ inches or _____ cms	

**B. INSURANCE INFORMATION**

Aetna Member ID #: _____	Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No
Group #: _____	If yes, provide ID#: _____ Carrier Name: _____
Insured: _____	Insured: _____
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____	Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____

**C. PRESCRIBER INFORMATION**

First Name:		Last Name:		(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.	
Address:		City:	State:	ZIP:	
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider Email:		Office Contact Name:		Phone:	
Specialty (Check one): <input type="checkbox"/> Allergist <input type="checkbox"/> Immunologist <input type="checkbox"/> Other: _____					

**D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION**

<b>Place of Administration:</b>		<b>Dispensing Provider/Pharmacy: (Patient selected choice)</b>	
<input type="checkbox"/> Self-administered	<input type="checkbox"/> Physician's Office	<input type="checkbox"/> Physician's Office	<input type="checkbox"/> Retail Pharmacy
<input type="checkbox"/> Outpatient Infusion Center	Phone: _____	<input type="checkbox"/> Specialty Pharmacy	<input type="checkbox"/> Other: _____
Center Name: _____		Name: _____	
<input type="checkbox"/> Home Infusion Center	Phone: _____	Address: _____	
Agency Name: _____		Phone: _____	Fax: _____
<input type="checkbox"/> Administration code(s) (CPT): _____		TIN: _____	PIN: _____
Address: _____			

**E. PRODUCT INFORMATION**

**Request is for: Haegarda (C1 esterase inhibitor, human) Dose:** \_\_\_\_\_ **Frequency:** \_\_\_\_\_

**F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.**

Primary ICD Code: \_\_\_\_\_ Secondary ICD Code: \_\_\_\_\_ Other ICD Code: \_\_\_\_\_

**G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.**

**For All Requests (clinical documentation required for all requests):**

Yes  No Is the requested medication being used for the prevention of hereditary angioedema (HAE) attacks?

Yes  No Will the requested medication be used in combination with any other medication used for the prophylaxis of hereditary angioedema (HAE) attacks?

Please indicate how many hereditary angioedema (HAE) attacks the patient has per month: \_\_\_\_\_

Yes  No Is the requested medication prescribed by or in consultation with a prescriber who specializes in management of hereditary angioedema (HAE)? Which of the following applies to the patient?

**Hereditary angioedema (HAE) with C1 inhibitor deficiency or dysfunction confirmed by laboratory testing**  
Please indicate which of the following conditions the patient has/had at the time of diagnosis:  
 A C1 inhibitor (C1-INH) antigenic level below the lower limit of normal as defined by the laboratory performing the test  
 A normal C1-INH antigenic level and a low C1-INH functional level (functional C1-INH less than 50% or C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test)  
 Other

**Hereditary angioedema (HAE) with normal C1 inhibitor confirmed by laboratory testing**  
Please indicate which of the following conditions the patient has/had at the time of diagnosis:  
 F12, angiotensin-converting enzyme 2, plasminogen, kininogen-1 (KNG1), heparan sulfate-glucosaminase 3-O sulfotransferase 6 (HS3ST6) or myoferlin (MYOF) gene mutation as confirmed by genetic testing  
 **Both** of the following: 1). Angioedema refractory to a trial of high-dose antihistamine therapy (i.e., cetirizine at 40 mg per day or the equivalent) for at least one month **AND** 2). Family history of angioedema  
 Other

Continued on next page



**Haegarda® (C1 esterase inhibitor, human)  
Medication Precertification Request**

Page 2 of 2

(All fields must be completed and legible for precertification review.)

**Aetna Precertification Notification**

Phone: 1-866-752-7021

FAX: 1-888-267-3277

**For Medicare Advantage Part B:**

Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

**G. CLINICAL INFORMATION (continued) – Required clinical information must be completed in its entirety for all precertification requests.**

**For Continuation of Therapy Requests (clinical documentation required for all requests):**

- Yes  No Has the patient experienced a significant reduction in frequency of acute attacks (e.g., >= 50%) since starting treatment?  
 Yes  No Has the patient reduced the use of medications to treat acute attacks since starting treatment with the requested medication?

**H. ACKNOWLEDGEMENT**

**Request Completed By (Signature Required):** \_\_\_\_\_ **Date:** \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.